Durable complete response after discontinuation of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma with portal vein tumor thrombosis: the first report
- Author:
Pramod KUMAR
1
;
Pradeep KRISHNA
;
Rohit MAIDUR
;
Naveen CHANDRASHEKHAR
;
Suresh RAGHAVAIAH
Author Information
- Publication Type:Case Report
- From:Journal of Liver Cancer 2025;25(1):134-137
- CountryRepublic of Korea
- Language:English
- Abstract: Hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is associated with a dismal prognosis. Atezolizumab plus bevacizumab (atezo-bev) is the recommended palliative treatment, and approximately 10% of the patients may experience a complete response (CR), according to the mRECIST criteria. The treatment duration is until disease progression or unacceptable side effects occur. Long-term continuation can cause potential toxicities and a substantial financial burden, making early treatment discontinuation a viable option. This report describes durable CR after discontinuing atezo-bev treatment in three patients with HCC and PVTT.
